Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
AMRN 
Amarin Corporation PLC (AMRN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: AMRN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -8.96% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 183.07M USD | Price to earnings Ratio - | 1Y Target Price 1 |
Price to earnings Ratio - | 1Y Target Price 1 | ||
Volume (30-day avg) 1687790 | Beta 1.83 | 52 Weeks Range 0.35 - 1.11 | Updated Date 04/2/2025 |
52 Weeks Range 0.35 - 1.11 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.2 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date 2025-03-12 | When - | Estimate -0.03 | Actual -0.02 |
Profitability
Profit Margin -35.95% | Operating Margin (TTM) -25.76% |
Management Effectiveness
Return on Assets (TTM) -4.56% | Return on Equity (TTM) -15.83% |
Valuation
Trailing PE - | Forward PE 500 | Enterprise Value -103426658 | Price to Sales(TTM) 0.8 |
Enterprise Value -103426658 | Price to Sales(TTM) 0.8 | ||
Enterprise Value to Revenue 0.08 | Enterprise Value to EBITDA -5.8 | Shares Outstanding 414185984 | Shares Floating 377750328 |
Shares Outstanding 414185984 | Shares Floating 377750328 | ||
Percent Insiders 1.63 | Percent Institutions 20.18 |
Analyst Ratings
Rating 2.33 | Target Price 1 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell 2 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Amarin Corporation PLC
Company Overview
History and Background
Amarin Corporation PLC was founded in 1993. It initially focused on developing treatments for cardiovascular disease. A key milestone was the development and FDA approval of Vascepa. Its evolution involved shifting its focus to prescription omega-3 fatty acid products.
Core Business Areas
- Pharmaceutical Development and Commercialization: Focuses on the development and commercialization of therapies for cardiovascular health, primarily Vascepa.
Leadership and Structure
The leadership team consists of executives with experience in pharmaceuticals and commercial operations. The organizational structure includes departments for research and development, commercial operations, finance, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Vascepa: Vascepa (icosapent ethyl) is a prescription omega-3 fatty acid medication derived from fish oil used to reduce cardiovascular risk in adults with elevated triglyceride levels. Market share data is dynamic and impacted by generic competition; revenue figures have significantly decreased since generics entered the market. Competitors include generic versions of icosapent ethyl, Lovaza (GSK), and dietary supplements containing omega-3 fatty acids.
Market Dynamics
Industry Overview
The pharmaceutical industry focusing on cardiovascular health is highly competitive. There is increasing demand for therapies to reduce cardiovascular risk. The market faces challenges from generic competition and evolving treatment guidelines.
Positioning
Amarin was initially a leader in the prescription omega-3 market with Vascepa. Generic competition has significantly eroded its market share. It now focuses on defending intellectual property and exploring new formulations.
Total Addressable Market (TAM)
The global cardiovascular disease market is substantial, estimated in hundreds of billions of dollars. Amarin's positioning within this TAM is now more niche, focusing on specific patient populations where Vascepa may still offer a benefit over generics.
Upturn SWOT Analysis
Strengths
- Established brand recognition (Vascepa)
- Clinical trial data supporting efficacy of Vascepa
- Experienced management team
- Existing distribution network
Weaknesses
- Dependence on a single product (Vascepa)
- Generic competition eroding market share
- Litigation costs related to patent defense
- Limited pipeline of new products
Opportunities
- Develop new formulations of icosapent ethyl
- Expand into new markets geographically
- Acquire or license new cardiovascular therapies
- Focus on patient populations where generics are less effective
Threats
- Continued generic erosion of Vascepa sales
- Changes in regulatory guidelines
- Increased competition from other pharmaceutical companies
- Pricing pressures from payers
Competitors and Market Share
Key Competitors
- GNPK
- GSK
- PRVA
Competitive Landscape
Amarin's advantage lies in its clinical data for Vascepa. Its disadvantage is its dependence on a single product facing generic competition.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth was strong before generic competition. Recent years have shown significant decline.
Future Projections: Future growth projections are uncertain, dependent on successful patent defense and development of new products. Analyst estimates are generally cautious.
Recent Initiatives: Amarin is focused on intellectual property protection and exploring new formulations and markets for Vascepa.
Summary
Amarin is a company facing significant challenges due to generic competition for its key product, Vascepa. While it has strong clinical data supporting Vascepa's efficacy, declining sales and increased competition impact its financial performance. Future success depends on successful intellectual property defense and development of new growth opportunities. The company needs to strategically focus on niche markets or new product innovation to restore profitability.
Similar Companies
GSK
GlaxoSmithKline PLC ADR
GSK
GlaxoSmithKline PLC ADR
PRVA
Privia Health Group Inc
PRVA
Privia Health Group Inc
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Amarin Corporation PLC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1993-04-01 | CEO, President & Director Mr. Aaron D. Berg | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 275 | Website https://www.amarincorp.com |
Full time employees 275 | Website https://www.amarincorp.com | ||
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States and Europe. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.